
Kontigo Care - Well-positioned to meet the demand for immediate drug detection

Redeye reiterates its valuation following the Q2 2024 report, which was stronger than our expectations overall. Given the challenging macro climate, the business performed well, accompanied by solid cost control. The outlook remains cautiously optimistic in the short term. However, we are confident about the potential of the newly launched Previct Drug and Previct Safety, which have garnered significant attention both in Sweden and internationally, as well as from adjacent sectors.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Kontigo Care - Well-positioned to meet the demand for immediate drug detection](#)